Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting
Celgene Corporation (NASDAQ:CELG) today announced detailed results from the phase III RADIANCE™ Part B trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, versus a first-line treatment, Avonex® (interferon beta-1a) (IFN), in patients with relapsing multiple sclerosis (RMS). The results were presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting, which was held in Paris, October 25-28, 2017.
“As physicians, we recognize the increased need for additional effective and safe therapeutic options for use earlier in the treatment of RMS,” said Bruce Cree, M.D., Ph.D., M.A.S., Associate Professor of Clinical Neurology at the University of California San Francisco Weill Institute for Neurosciences and an author of the abstract. “Based on these data, ozanimod has the potential to provide RMS patients and their physicians a novel oral option for treating this debilitating illness.”
The RADIANCE Part B study evaluated two doses (1 mg and 0.5 mg) of oral ozanimod compared with IFN in 1,320 patients with RMS in 21 countries treated for two years. A significant reduction in annualized relapse rate (ARR) was demonstrated for ozanimod 1 mg (ARR=0.17, p<0.0001) and for ozanimod 0.5 mg (ARR=0.22, p=0.0167) compared with IFN (ARR=0.28) over two years of treatment.
A significant reduction in new or enlarging T2 lesions was demonstrated for ozanimod 1 mg (42 percent, p<0.0001) and 0.5 mg (34 percent, p=0.0001) compared with IFN. A significant reduction in gadolinium-enhanced MRI lesions was also demonstrated for ozanimod 1 mg (53 percent, p=0.0006) and ozanimod 0.5 mg (47 percent, p=0.0030) compared with IFN.
In RADIANCE Part B, a reduction in brain volume loss, a measure associated with MS disease progression, was observed for both ozanimod doses compared with IFN. Whole brain volume loss was reduced by 27 percent with the 1 mg dose of ozanimod (median percent change from baseline to 2 years: -0.69, nominally significant p<0.0001) and by 25 percent in the 0.5 mg group (-0.71, nominally significant p <0.0001) versus IFN (-0.94) at two years.
In a pre-specified pooled analysis of the SUNBEAM™ and RADIANCE Part B studies, ozanimod did not reach statistical significance compared with IFN in the time to 3-month confirmed disability progression. A very low rate of disability progression was observed across all treatment groups. Of the 2,659 patients assessed, the number of patients with 3-month confirmed disability progression by the end of the study was 67 (7.6 percent) patients in the ozanimod 1 mg group and 58 (6.5 percent) in the ozanimod 0.5 mg group compared with 69 (7.8 percent) in the IFN group. In RADIANCE Part B, the number of patients with 3-month confirmed disability progression by the end of the study was 54 (12.5 percent) in the ozanimod 1 mg group and 41 (9.3 percent) in the ozanimod 0.5 mg group compared with 50 (11.3 percent) in the IFN group.
Treatment-emergent adverse events (AEs) were experienced by 75 percent of patients on ozanimod 1 mg, 74 percent on ozanimod 0.5 mg and 83 percent on IFN. Most AEs were mild; the most common AEs across all treatment groups were nasopharyngitis, headache, alanine aminotransferase increased, influenza-like illness, hypertension, gamma-glutamyl transferase increased, pharyngitis and urinary tract infection. AEs of alanine aminotransferase increased were low, transient and generally resolved without study drug discontinuation. The overall incidences of serious AEs were low and similar across treatment arms (ozanimod 1 mg, 6.5 percent; 0.5 mg, 7.1 percent; IFN, 6.4 percent). The percentages of patients who discontinued study drug due to AEs were 3.0 percent for ozanimod 1 mg, 3.2 percent for ozanimod 0.5 mg and 4.1 percent for IFN.
No second degree or higher atrioventricular blocks were observed. Serious cardiac AEs were 0.0 percent for ozanimod 1 mg, 0.7 percent for ozanimod 0.5 mg and 0.5 percent for IFN. Infection rates were similar across treatment arms; serious infection rates were low and similar across treatment arms, with no serious opportunistic infections.
The overall safety and tolerability profile was consistent with results from the previously reported phase II RADIANCE Part A and phase III SUNBEAM studies in RMS.
“Given the totality of the data for ozanimod, we believe that the benefit-risk profile supports pursuing ozanimod as a potential new oral therapeutic option and look forward to filing regulatory submissions in the U.S. by the end of 2017 and in the EU in the first half of 2018,” said Terrie Curran, President, Celgene Inflammation and Immunology.
Celgene will host a live webcast from the MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting today at 12 p.m. EDT (6 p.m. CEST). Members of Celgene's management team and clinical investigators will discuss the data presentations at the ECTRIMS Meeting. The webcast will be available in the Investor Relations section of the Company's website at www.celgene.com.
RADIANCE Part B is a pivotal, phase III, multicenter, randomized, double-blind, double-dummy, active-controlled trial evaluating the efficacy, safety and tolerability of two doses of oral ozanimod (1 mg and 0.5 mg) against weekly intramuscular interferon beta-1a (Avonex®) over a 24-month treatment period. The study included 1,320 people living with RMS across 147 sites in 21 countries.
The primary endpoint of the trial was ARR over 24 months. The secondary MRI endpoints were number of new or enlarging hyperintense T2-weighted brain MRI lesions over 24 months, number of gadolinium-enhanced brain MRI lesions at month 24 and percent change from baseline in brain volume at month 24.
An analysis of the time to onset of 3-month confirmed disability progression was pre-specified using pooled data from both the SUNBEAM and RADIANCE Part B phase III trials.
SUNBEAM is a pivotal, phase III, multicenter, randomized, double-blind, double-dummy, active-controlled trial evaluating the efficacy, safety and tolerability of two doses of oral ozanimod (1 mg and 0.5 mg) against weekly intramuscular interferon beta-1a (Avonex®) over a 12-month treatment period. The study included 1,346 people living with RMS across 152 sites in 20 countries.
The primary endpoint of the trial was ARR during the treatment period. The secondary MRI endpoints were number of new or enlarging hyperintense T2-weighted brain MRI lesions over 12 months, number of gadolinium-enhanced brain MRI lesions at month 12 and percent change from baseline in brain volume at month 12.
An analysis of the time to onset of 3-month confirmed disability progression was pre-specified using pooled data from both the SUNBEAM and RADIANCE Part B phase III trials.
Ozanimod is a novel, oral, selective, sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator in development for immune-inflammatory indications including relapsing multiple sclerosis, ulcerative colitis and Crohn's disease. Selective binding with S1PR1 is believed to inhibit a specific sub set of activated lymphocytes from migrating to sites of inflammation. The result is a reduction of circulating T and B lymphocytes that leads to anti-inflammatory activity. Importantly, immune surveillance is maintained.
Selective binding with S1PR5 is thought to activate specific cells within the CNS. This has the potential to enhance remyelination and prevent synaptic defects. Ultimately, neurological damage may be prevented.
Ozanimod is an investigational compound that is not approved for any use in any country.
About Multiple Sclerosis
Multiple sclerosis (MS) is a disease in which the immune system attacks the protective myelin sheath that covers the nerves. The myelin damage disrupts communication between the brain and the rest of the body. Ultimately, the nerves themselves may deteriorate — a process that's currently irreversible. Signs and symptoms vary widely, depending on the amount of damage and the nerves affected. Some people living with MS may lose the ability to walk independently, while others experience long periods of remission during which they develop no new symptoms. Multiple sclerosis affects approximately 400,000 people in the U.S. and approximately 2.5 million people worldwide.
Relapsing multiple sclerosis (RMS) is characterized by clearly defined attacks of worsening neurologic function. These attacks — often called relapses, flare-ups or exacerbations — are followed by partial or complete recovery periods (remissions), during which symptoms improve partially or completely with no apparent progression of disease. RMS is the most common disease course at the time of diagnosis. Approximately 85 percent of patients are initially diagnosed with RMS, compared with 10-15 percent with progressive forms of the disease.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next‐generation solutions in protein homeostasis, immuno‐oncology, epigenetics, immunology and neuro‐inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission.
Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.
Patrick E. Flanigan III, 908-673-9969
Corporate Vice President, Investor Relations
Catherine Cantone, 908-897-4256
Senior Director, Corporate Communications
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
QNB Group: Financial Results for the Year Ended 31 December 201716.1.2018 16:26 | Tiedote
QNB Group, the largest financial institution in the Middle East and Africa (MEA) region, announced its results for the year ended 31 December 2017. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180116006048/en/ QNB Group HQ Building in Doha (Photo: AETOSWire) For the year ended 2017, Net Profit reached QAR13.1 billion (USD3.6 billion), up by 6% compared to last year. Total assets increased by 13% from December 2016 to reach QAR811 billion (USD223 billion), the highest ever achieved by the Group. The Board of Directors have recommended to the General Assembly for the distribution of a cash dividend of 60% of the nominal share value (QAR 6.0 per share). The financial results for 2017 along with the profit distribution are subject to Qatar Central Bank (QCB) approval. Key driver of total assets growth was from loans and advances which grew by 12% to reach QAR584 billion (USD161 billion). Also QNB Group increased customer deposi
H.I.G. Capital Acquires Majority Stake in Beinbauer Group16.1.2018 15:35 | Tiedote
H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €20 billion of equity capital under management, announced that one of its affiliates has acquired a majority interest in Beinbauer Group (“Beinbauer”). Beinbauer, headquartered in Büchlberg near Passau, Germany, is a leading provider of complex machined metal parts (iron, steel, aluminium) for the European on- and off-highway commercial vehicle industry (OEMs and other tier-1 suppliers). Beinbauer’s core competencies are the machining of components and assemblies in state-of-the-art production processes as well as building and managing complex supplier networks, offering its customers all-in-one solutions for axle, frame, chassis and engine parts from a single source. Beinbauer operates four production sites in Germany and has approximately 700 employees. In 2017, Beinbauer generated revenues of more than €200 million. The Beinbauer management team, headed by Tobias Lührig and Patric Meeth, will c
Bidgely Closes $27M Series C to Grow Artificial Intelligence Solution for Utilities and Energy Retailers16.1.2018 14:00 | Tiedote
U.S.-based Bidgely announced today the closing of a $27 million Series C round of financing, marking the largest round of investment to date for any energy disaggregation technology. Georgian Partners, an investment fund known for its focus on high-growth enterprise software companies that use applied artificial intelligence to disrupt markets, led the oversubscribed round. Returning investors include Khosla Ventures, E.ON, and innogy. Constellation Technology Ventures, the venture capital arm of Exelon Corporation, is also expected to return. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180116005615/en/ Bidgely Energy Usage Itemisation (Photo: Business Wire) “We invest in high-growth SaaS companies that are applying AI to solve real-world business problems,” said Simon Chong, Managing Partner at Georgian Partners. “Bidgely is using machine learning to fundamentally reinvent customer engagement with utilities and enable a n
Glennmont Seeks More Than 500MW of Investment Opportunities in Clean Energy Infrastructure Assets with Expanded Investment Capacity16.1.2018 13:19 | Tiedote
Glennmont Partners has expanded its investment capacity in the clean energy infrastructure space and now has three funds under management – these are Fund I (2010) and Fund II (2013), which are fully invested, and now a new third Fund (2017). Opportunities are being sought for a portfolio of clean energy infrastructure projects in Europe. Glennmont is one of Europe’s largest investors focusing exclusively on investment in clean energy infrastructure. This announcement follows the successful refinancing of Glennmont’s 245MW Italian wind portfolio in October and the refinancing of the Sleaford straw-fired biomass plant in September - amounting to around €340m of capital raised over the course of 2017. Glennmont’s strategy remains consistent with its past experiences: it seeks to invest in solar PV, offshore and onshore wind, bioenergy and small-scale hydro across the EEA; it will target to-be-built and recently operational assets with stable, predictable cash yields underpinned by regula
Breed Reply Portfolio of IoT Start-Ups Raise in Excess of $50 Million in Series A Funding in 201716.1.2018 13:00 | Tiedote
Breed Reply, a leading operational investor in early-stage internet of things (IoT) businesses, saw one third of its 18-strong portfolio of investee companies, complete series A funding rounds in 2017. In total, six companies raised in excess of $50 million during the year with funds coming from notable investors including Accel, Aviva Ventures, Finance Wales, Intu and MunichRE. More companies in the growing portfolio are expected to be ready for Series A investment in 2018. The successful companies span a broad range of IoT sectors: Callsign (Cyber Security); Cocoon (Smart Home); enModus (Smart Building); Senseye (Industrial); WePredict (Big Data); and Zeetta Networks (Platforms). Helping start-ups prepare for future funding is a crucial part of Breed Reply’s commitment to companies when it invests. As an active operational investor, Breed Reply works closely with management to accelerate the company’s development to achieve Series A funding and beyond. The team has significant experi
MagicStay Raises 1.5 Million Euros to Accelerate Its Development16.1.2018 13:00 | Tiedote
The short-term rental start-up for business travelers MagicStay.com , has just finalized a new round of fundraising to continue its development. Just four years since its release, the rental platform already offers 150,000 apartments in 90 countries and has taken a leading position in the alternative accommodation industry. The fundraising totaling 1.5 million Euros was led by the start-up’s main shareholders (Michaël Benabou, Benoit Bassi, Patrick Lucas, Nicolas Quenedey or Charles Petruccelli, former CEO of American Express Global Business Travel...), as well as new investors, including Marc Frappier, Managing Partner of Eurazeo and Head of Eurazeo Capital, Thibault Basquin, Managing Director of Ardian, Nicolas Santi-Weil, CEO of AMI Paris... This round table will let the start-up accelerate its exclusive technological development for employees of large companies to book secure apartments as easily as hotel rooms, via either existing booking tools (Hotel Booking Tool, Self Booking To
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme